Johnson & Johnson (JNJ) Stock
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Johnson & Johnson is led by CEO Joaquin Duato, employs 138,100 people, headquartered in New Brunswick, US, publicly traded since 1943.
Johnson & Johnson (JNJ) stock trades at $259.24 with a market capitalization of $624.74B. The stock is valued at a price-to-earnings (P/E) ratio of 29.91, price-to-book of 7.81, price-to-sales of 6.48. Over the past 52 weeks the stock has ranged between $154.21 and $269.58, and currently trades 3.8% below its 52-week high. It pays a dividend yielding 2.07%.
On profitability, Johnson & Johnson generates a return on equity (ROE) of 26.26% — well above the market average, a sign of a high-quality business, return on capital employed of 18.08%, an operating margin of 26.87%, a net profit margin of 21.83%.
In its most recent fiscal year, Johnson & Johnson reported annual revenue of $94.2B, net profit of $26.8B, revenue has compounded at 2.7% a year over the last five years, profit at 12.7% a year. Profit growing faster than revenue points to expanding margins.
The balance sheet shows a debt-to-equity ratio of 0.68, a current ratio of 1.03, total assets of $199.2B, $19.7B in cash and equivalents.
JNJ has an average daily trading volume of 8,527,842.2 shares, a beta of 0.23 (less volatile than the overall market).
Official website: www.jnj.com